CIP2A expression in Bortezomib-treated multiple myeloma

Area of Science:

• Oncology
• Molecular Biology
• Hematology

Background:

• Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
• Understanding molecular markers for prognosis and treatment response is crucial for improving MM patient outcomes.
• CIP2A (Cancerous inhibitor of protein phosphatase 2A) is implicated in various cancers, but its role in MM requires further elucidation.

Purpose of the Study:

• To investigate the expression levels of CIP2A in patients with multiple myeloma (MM).
• To evaluate the prognostic significance of CIP2A expression in MM.
• To assess the impact of Bortezomib-Dexamethasone (BD) treatment on CIP2A expression in MM.

Main Methods:

• Real-time quantitative polymerase chain reaction (QRT-PCR) was used to measure CIP2A expression.
• CIP2A levels were analyzed in 33 newly diagnosed MM patients and 15 healthy controls.
• Expression was assessed at diagnosis and after four cycles of BD regimen.

Main Results:

• CIP2A expression was significantly upregulated in MM patients compared to healthy controls.
• Treatment with the BD regimen led to a significant reduction in CIP2A expression.
• High CIP2A expression (>16.45 EU) was associated with poorer response to BD therapy (p=0.005) and shorter progression-free survival (PFS) (p=0.006).

Conclusions:

• CIP2A is overexpressed in multiple myeloma and its expression is downregulated by bortezomib.
• Elevated CIP2A levels serve as a poor prognostic indicator in MM, correlating with reduced PFS and diminished response to BD.
• Targeting CIP2A for suppression presents a potential therapeutic strategy to enhance treatment outcomes in MM.